Chimeric antigen receptor T-Cell (CAR-T) immunotherapy has been regarded as one of the most promising methods for cancer therapy. How to verify CAR-T cell function and efficiency is very significant for clinical applications. Meanwhile, the identification of tumor cells/tissues is very important for tumor diagnosis and operation. In this study, biocompatible and mass-produced polydopamine (PDA) nanodots have been prepared by a facile method. Oxidized polydopamine (OPDA) can be synthesized by the reaction between PDA and hydrogen peroxide at atmospheric pressure and temperature, and it possesses both one-photon and two-photon fluorescence properties. OPDA nanodots can image living cells for long time periods without mitosis and proliferation inhibition. After ingestion of OPDA nanodots, Raji cells can be used to verify CAR-T cell lethality and efficiency by visualization through fluorescence. The fluorescence intensity change originating from the conversion of PDA into OPDA can function as a signal to identify the tumor and normal cells/tissues because of the different concentration of ROS in tumor cells (high) and normal cells (low). Therefore, the facile synthesis of mass-produced novel organic nanodots with two-photon fluorescence properties will have wide applications in long time living cell imaging without mitosis and proliferation inhibition, CAR-T cell function verification and tumor cell/tissue detection.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8tb01930dDOI Listing

Publication Analysis

Top Keywords

car-t cell
16
cell function
12
function verification
8
verification tumor
8
tumor cell/tissue
8
cell/tissue detection
8
verify car-t
8
two-photon fluorescence
8
fluorescence properties
8
opda nanodots
8

Similar Publications

Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.

Clin Kidney J

January 2025

Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.

Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and tumour lysis syndrome.

View Article and Find Full Text PDF

Resistance to the currently available treatment paradigms is one of the main factors that contributes to poor outcomes in patients with advanced cervical cancer. Novel targeted therapy approaches might enhance the patient's treatment outcome and are urgently needed for this malignancy. While chimeric-antigen receptor (CAR)-based adoptive immunotherapy displays a promising treatment strategy for liquid cancers, their use against cervical cancer is largely unexplored.

View Article and Find Full Text PDF

Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T-Cell Therapy.

Mov Disord Clin Pract

January 2025

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Dvision of Neurology, Toronto Western Hospital, UHN, Krembil Brain Institute, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF

T cell malignancies after CAR T cell therapy in the DESCAR-T registry.

Nat Med

January 2025

Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France.

The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.

View Article and Find Full Text PDF

Chimeric antigen receptor T cells (CAR T cells) with T stem (T) cell-like phenotypic characteristics promote sustained antitumor effects. We performed an unbiased and automated high-throughput screen of a kinase-focused compound set to identify kinase inhibitors (KIs) that preserve human T cell-like CAR T cells. We identified three KIs, UNC10225387B, UNC10225263A and UNC10112761A, that combined in vitro increased the frequency of CD45RACCR7TCF1 T cell-like CAR T cells from both healthy donors and patients with cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!